Shattuck Labs, Inc., a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, announced that Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, will participate in two upcoming conferences.
April 30, 2021
· 1 min read